Anticholinergic Medicines and Cognitive Health in Older Adults
Medicines with anticholinergic properties can affect memory, attention, alertness and the speed of thinking in later life. These effects may be subtle, temporary or severe, depending on the medicine, dose, duration of use, kidney function and a person’s overall health.
The issue is especially relevant when several prescriptions and over-the-counter products are taken together. Understanding anticholinergic burden helps clinicians, families and older Australians distinguish medication-related cognitive change from dementia, depression, infection or other neurological conditions.
Why Anticholinergic Load Matters
Acetylcholine is a neurotransmitter involved in learning, memory, concentration and automatic body functions. Anticholinergic medicines reduce acetylcholine activity. This can be useful for conditions such as bladder urgency, allergies, depression, Parkinson’s disease and gastrointestinal spasms, yet the same action may impair cognitive performance.
Anticholinergic burden refers to the combined effect of medicines with these properties. A person may take a low-risk medicine without difficulty, then develop confusion after adding another product with a similar effect. Older adults are more vulnerable because ageing can alter drug metabolism, blood–brain barrier function and sensitivity to central nervous system effects.
Changes in Memory and Attention
Common cognitive effects include short-term memory problems, slower information processing, reduced concentration and difficulty finding words. Some people report feeling mentally “foggy”, while others may appear disengaged or unusually sleepy. These changes can interfere with medication management, driving, finances and social participation.
A sudden deterioration is more concerning than a gradual, stable complaint. Acute confusion, hallucinations, agitation or marked drowsiness can indicate delirium, particularly after surgery, hospital admission, dehydration or an infection. Cognitive symptoms should be assessed promptly rather than automatically attributed to ageing.
Medicines That Add to the Burden
Examples include oxybutynin for overactive bladder, amitriptyline and paroxetine for mood disorders, promethazine and some antihistamines for allergies, and certain medicines used in Parkinson’s disease. Some sleep aids and cold-and-flu products sold without a prescription may also have anticholinergic activity.
The total exposure matters more than one label on a medicine packet. A pharmacist or doctor can review prescription drugs, complementary products and pharmacy purchases, then consider alternatives. Older adults should not stop antidepressants, bladder medicines or other regular treatments suddenly without professional guidance.
Australian Context and Everyday Risk
In Australia, an older person may collect prescriptions through a community pharmacy in Brisbane, Melbourne or Perth while also buying sedating antihistamines for hay fever or sleep. Hot weather, inadequate fluid intake and long travel distances can worsen dizziness, constipation, urinary retention and confusion. These risks can be greater for people living alone or managing several chronic conditions.
The Therapeutic Goods Administration regulates medicines, while the Pharmaceutical Benefits Scheme influences access to many prescription treatments. However, a medicine’s PBS availability does not mean it is suitable for every older person. Australian clinicians commonly use medication reviews and deprescribing principles to reduce potentially inappropriate medicines, with attention to the individual’s goals and daily routine.
Assessment and Cultural Safety
A cognitive assessment should explore when symptoms began, which medicine changes preceded them and whether difficulties fluctuate during the day. Testing can be affected by anxiety, fatigue, hearing loss, language background and unfamiliar clinical settings; practical guidance on assessment anxiety can help clinicians interpret results more fairly.
Cultural and linguistic factors also matter for Aboriginal and Torres Strait Islander peoples, migrants and multilingual families. Familiar examples, interpreters and collateral information from relatives may produce a more accurate picture of everyday functioning. Research discussions, including student cultural research, show why culture should be treated as part of clinical context rather than an afterthought.
Safer Prescribing and Deprescribing
The first step is a complete medicines reconciliation, including products kept in the bathroom cabinet or bought from supermarkets and pharmacies. Clinicians may consider non-drug approaches, a lower-anticholinergic alternative, dose reduction or gradual withdrawal. For bladder symptoms, scheduled toileting and pelvic-floor strategies may complement treatment; for insomnia, behavioural approaches can be preferable to sedating medicines.
Monitoring after a change is essential. Families can record alertness, falls, bowel function, urinary symptoms, sleep and daily activities. A safer plan balances cognitive health with the condition being treated, since untreated pain, depression, allergy symptoms or bladder problems can also reduce quality of life.
Evidence, Communication and Clinical Practice
Neuropsychology brings together medication review, cognitive testing and humane communication. Conference resources from the INS 2018 meeting reflect this connection between neuroscience, clinical practice and patient-centred care. Clear explanations help older adults understand that a medicine may contribute to symptoms without implying that anyone has made a prescribing error.
The following comparison summarises patterns clinicians may consider during review:
| Medicine or exposure pattern | Possible cognitive effect | Practical review point |
|---|---|---|
| One low-dose anticholinergic | Mild dry mouth, slowed attention or no obvious change | Check symptoms after starting or increasing |
| Several medicines with anticholinergic activity | Memory problems, drowsiness, constipation or falls | Calculate overall burden and seek alternatives |
| Recent dose increase or new medicine | Sudden confusion or reduced alertness | Review timing and assess for delirium |
| Long-term use in a frail older adult | Persistent cognitive slowing and functional decline | Consider a supervised deprescribing plan |
| Anticholinergic medicine plus heat, dehydration or illness | Greater confusion, dizziness or urinary retention | Address acute risks and obtain medical review |
Recognising medication-related cognitive effects can prevent avoidable harm while preserving treatments that genuinely benefit an older person. Regular review, culturally appropriate assessment and shared decisions are central to safer ageing.
General Information
Important information about the meetingIndustry
Support and exhibition opportunitiesCzech Republic
Beautiful country situated in the very heart of EuropeContact
How can we help you?
Prague Congress Centre (KCP)
5.května 65140 21 Prague 4
Czech Republic
Phone: +420 261 171 111
Website: www.kcp.cz